Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionable

Once buoyed by demand for COVID-19 vaccines and treatments, the biotech industry is experiencing a sobering leveling out
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.